Quest Diagnostics (DGX) Stock Forecast & Price Target

Quest Diagnostics demonstrates a robust financial performance, highlighted by a 13.1% year-over-year revenue growth, reaching $2.82 billion, which surpassed both internal and consensus expectations. The company’s physician channel exhibited strong growth at approximately 17% year-over-year, bolstered by broad-based demand and expanded health plan coverage, while the consumer-initiated testing segment surged between 30% and 40% year-to-date, indicating a significant shift in consumer engagement. Additionally, the year-to-date cash flow from operations increased by 63.1% year-over-year, reflecting higher operating income and enhanced working capital management, further solidifying a positive outlook for the company.

Quest Diagnostics's revenue per requisition decreased by 0.1%, which is concerning as this metric is below expectations and indicates challenges in maintaining pricing power, especially with lower revenue-generating volumes from Corewell and Fresenius. Additionally, the anticipated flat pricing for 2026 suggests that the company may struggle to achieve revenue growth, exacerbated by investments in new projects which have led to a year-over-year decline in Adjusted Operating Income (AOI) margin. Furthermore, the decline in cash flow from operations, largely driven by one-time benefits in the prior year, raises concerns about the company's financial stability moving forward.